Senti Biosciences Holdings, Inc.: Nantahala Capital Management, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Nantahala Capital Management amended its Schedule 13G filing for Senti Biosciences Holdings, disclosing a change in its passive stake in the gene-therapy developer. The amendment was filed with the SEC under accession number 0001104659-26-127177. The filing does not specify the size or direction of the position change in the headline disclosure. The update matters because 13G amendments signal shifts in institutional ownership that can influence sentiment in a thinly traded small-cap biotech. Investors will watch for the full filing details on the exact share count and percentage held, and for any subsequent 13D or 13G filings that clarify Nantahala's intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Nantahala Capital Management, LLC, Senti Biosciences Holdings, Inc.